Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 712-714, 2009. First published February 20, 2009; 10.1373/clinchem.2008.115972
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.115972v1
55/4/712    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eby, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eby, C. S.
(Clinical Chemistry. 2009;55:712-714.)
© 2009 American Association for Clinical Chemistry, Inc.

Point/Counterpoint

Counterpoint: Pharmacogenetic-Based Initial Dosing of Warfarin: Not Ready for Prime Time

Charles S. Eby1,a

1 Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO.

aAddress correspondence to this author at: Department of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110. Fax 314-362-1461; e-mail eby@wustl.edu.

The first 20% of the full text of this article appears below.

Availability of the human genome sequence offers the promise of personalized medicine through pharmacogenomics. Warfarin, a member of the coumarin family of oral anticoagulants used to prevent and treat thromboembolic disorders and one of the top 20 prescribed medications in the US, is an ideal drug for applying the principles of pharmacogenetics. Warfarin inhibits reduction of vitamin K epoxide by the vitamin K epoxide reductase complex, subunit 1 (VKORC1)1 enzyme, causing hypogammacarboxylation of vitamin K–dependent coagulation factors and an acquired coagulopathy. Warfarin therapy is monitored with the international normalized ratio (INR) derived from the prothrombin time. The INR therapeutic range is narrow, and the maintenance warfarin dose required to produce a therapeutic INR for an individual is both unpredictable and widely variable, leading to bleeding complications, especially during the initiation period when dose adjustments are made by trial and error(1).

During the past 12 years, discoveries regarding the molecular basis of warfarin pharmacokinetics and pharmacodyanmics have been combined with clinical and demographic information from stably anticoagulated patients to generate many dosing algorithms. Up to 54% of the interpatient variation in therapeutic warfarin dose can be accounted for by the combination of patient age, body size, target INR, and use of amiodaron with the genotypes for 2 single-nucleotide polymorphisms (SNPs) in cytochrome 2C9 that reduce warfarin metabolism and 1 from a group of SNPs in the vitamin K epoxide reductase complex, . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.